

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2015 THIRD QUARTERLY REPORT

13.09(2) 13.10B G
L I E H I K I L I I I
P I L A F I (C . 571 L H I
K I).

2015 F (G) C .
L .* ("Company", "Group").
C A I B E

B B
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

29 2015

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

* for identification purposes only

1. IMPORTANT NOTICE

1.1 ("Board") ("Supervisory Committee") C I

1.2 A C B I G

1.3 C J D A I D (A I) C F

1.4 G

E

Ci : MB

Items	Amounts during the Reporting Period (Jul - Sep 2015)	Amounts from the beginning of the year to the end of the Reporting Period (Jan - Sep 2014)	Description
	97,665,175.84	191,310,773.56	M G
G			

						73,142
The shareholding status of the Top 10 shareholders						
Name of shareholders (full name)	Shareholding at the end of the period	Percentage (%)	Number of restricted shares held	Shares pledged or locked up		Capacity
				Status	Number	
HANGHAI FOUNDRY HIGH TECHNOLOGY (GROUP) COMPANY LIMITED ("F. G.")	920,641,314	39.83	0	N/A	0	
HK CC NOMINEE LIMITED (N/A)	402,619,300	17.42	0	N/A	0	
CHINA ECONOMIC FINANCE CORPORATION LIMITED	69,112,399	2.99	0	N/A	0	
NATIONAL SOCIAL ECONOMIC FUND 104 FOLIO*	37,199,998	1.61	0	N/A	0	
HONG KONG ECONOMIC CLEARING COMPANY LIMITED (N/A)	33,556,005	1.45	0	N/A	0	
CENTRAL HUIJIN INVESTMENT LTD.	24,067,700	1.04	0	N/A	0	
INHA LIFE INSURANCE CO., LTD. — DIVIDEND — GROUP DIVIDEND — 018L — FH001 HANGHAI*	22,652,864	0.98	0	N/A	0	
WING CAPITAL (BEIJING) CO., LTD — WING CAPITAL GROUP HOLDING FUND NO. 1*	17,695,247	0.77	0	N/A	0	
FOLIC INVESTING ELECTED 1*	16,764,537	0.73	0	N/A	0	
WING AN INVESTMENT CO., LTD — ELITE INVESTMENT • WING CAPITAL	16,567,783	0.72	0	N/A	0	

3. SIGNIFICANT EVENTS

3.1

Ci... MB

Balance Sheet				
Items	Closing balance as at the end of the period	Opening balance as at the beginning of the year	Ratio of change	Reasons
Q	485,549,599.95	198,755,576.52	144.29%	M
A		990,340,787.62	-100.00%	(N)
Q	3,494,730.03	11,246,964.92	-68.93%	M
A	3,529,897,004.62	2,499,156,438.67	41.24%	M
D	167,214,321.23	89,379,481.02	87.08%	M &D
	4,508,065,870.77	2,841,223,392.47	58.67%	M
	474,418,367.92	342,926,461.15	38.34%	M
D	14,831,357.70	1,279,819.25	1,058.86%	M
L		589,118,424.34	-100.00%	(N)
N	2,822,255,623.13	1,109,525,523.85	154.37%	M
Q	63,116,411.43	1,070,561,681.96	-94.10%	M
L	1,618,247,844.35	771,191,646.56	109.84%	M
B	1,894,480,886.28	3,085,482,735.30	-38.60%	M

Income Statement				
Items	Current amount	Amount of the last period	Ratio of change	Reasons
	Jan - Sep 2015	Jan - Sep 2014		
F	339,686,256.62	251,024,209.33	35.32%	M
A	33,340,027.70	11,784,007.60	182.93%	M
G	3,506,487.53	-9,516,778.44	136.85%	M
N	63,499,502.52	38,512,060.43	64.88%	M
N	10,862,409.73	15,531,263.99	-30.06%	M
Q	-279,141,519.38	146,057,212.28	-291.12%	M

Statement of Cash Flow				
Items	Current amount	Amount of the last period	Ratio of change	Reasons
	Jan - Sep 2015	Jan - Sep 2014		
N	1,161,951,526.99	843,637,595.71	37.73%	M
N	764,402,303.12	1,793,987,740.16	-57.39%	M

Note: I 2014, C L * (上海星藥業有限公司) (H I G i D F M (C L * (國藥控股國大 美藥業(上海)有限公司)), I E M C C L * (上海美益星大藥房連鎖有限公司) (H I G i D F M C L * (國藥控股國大 美大藥房上海連鎖有限公司)) B I G E M C C L * (北京金象大藥房醫藥連鎖有限責任公司) D I “A ” “

(3) 16 A 2015, 46
 B ()
 C 2015 ()
 C 246,808,510 A MB23.50
 C L * (中國人壽保險股份有限公司),
 C M A M C L * (招商財富資產管理有限公司),
 M A M C L * (泰康資產管理有限責任公司), C Fi
 M C L * (中信建投基金管理有限公司), C A M
 C L * (匯添富基金管理股份有限公司), A
 Fi C L * (安徽省鐵路建設投資基金有限公司), B
 M C L * (北京中融鼎新投資管理有限公司) E I D I G C
 L * (億利資源控股有限公司) C A

MB3,600,000,000
 A
 I
 2014
 C 21 A 2015,
 MB23.22
 249,784,664
 A

16 2015, 56
 B ()
 C 2015 ()
 C A C
 A A
 A A
 211,024,978
 MB4,899,999,989.16.

A C C
 C
 (4) 27 A 2015, 55
 B ()
 C MB5
 7
 C

Background	Type	Covenantors	Undertakings	Validity period	Whether duration specified	Whether timely and

3.4

N

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Prepared by: Chen Qiyu

29 October 2015

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2015

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash and cash equivalents	3,516,813,404.78	3,695,698,185.82
Accounts receivable		
Prepaid expenses and other receivables		
Inventory	38,724,495.54	33,770,584.14
Other current assets	408,527,911.80	472,523,132.71
Financial assets	1,789,464,377.02	1,504,149,790.72
Intangible assets	136,605,468.61	137,690,114.05
Investments in subsidiaries		
Investments in associates		
Investments in joint ventures		
Other non-current assets		
Other non-current assets	677,257.70	1,023,889.42
Derivatives	16,983,973.47	14,264,402.96
Other non-current assets	485,549,599.95	198,755,576.52
Other non-current assets		
Other non-current assets	1,627,321,198.79	1,604,562,390.25
Other non-current assets		990,340,787.62
Other non-current assets		
Other non-current assets	3,494,730.03	11,246,964.92
Other non-current assets	8,024,162,417.69	8,664,025,819.13
Non-current assets:		
Property, plant and equipment		
Intangible assets	3,529,897,004.62	2,499,156,438.67
Investments in subsidiaries		
Investments in associates		
Investments in joint ventures		
Other non-current assets	13,489,435,775.47	11,905,750,117.54
Other non-current assets		
Other non-current assets	4,720,292,409.25	4,623,958,317.63
Other non-current assets	964,172,888.14	1,051,988,109.53
Other non-current assets	3,233,982.94	5,450,698.63
Other non-current assets		
Other non-current assets		
Other non-current assets		
Other non-current assets	2,857,317,020.41	2,822,483,093.20
Other non-current assets	167,214,321.23	89,379,481.02
Other non-current assets	3,292,538,591.11	3,255,041,739.55
Other non-current assets	11,804,369.09	13,583,440.85
Other non-current assets	92,366,614.48	101,221,671.79
Other non-current assets	262,125,551.28	304,238,328.42
Other non-current assets	29,390,398,528.02	26,672,251,436.83
Other non-current assets	37,414,560,945.71	35,336,277,255.96

Consolidated balance sheet (Continued)

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
	4,508,065,870.77	2,841,223,392.47
B		
D		
L		
F		
B	67,928,606.53	70,987,451.05
	874,465,599.33	833,974,948.21
	226,002,022.22	266,518,255.34
G		
F		
	296,895,628.48	298,472,746.11
	474,418,367.92	342,926,461.15
I	166,803,873.32	177,075,081.31
D	14,831,357.70	1,279,819.25
	1,379,103,280.44	1,935,656,885.83
I		
A		
A		
L		589,118,424.34
N	2,822,255,623.13	1,109,525,523.85
	63,116,411.43	1,070,561,681.96
	10,893,886,641.27	9,537,320,670.87
Non-current liabilities:		
L	1,618,247,844.35	771,191,646.56
B	1,894,480,886.28	3,085,482,735.30
L	890,883,419.71	710,056,624.65
A		
D	178,123,561.73	139,593,190.51
D	1,934,427,964.42	1,929,331,107.42
	73,391,869.13	60,299,392.99
	6,589,555,545.62	6,695,954,697.43
	17,483,442,186.89	16,233,275,368.30
Equity:		
	2,311,380,364.00	2,311,611,364.00
C	6,049,708,237.59	6,123,454,191.14
L		
	838,468,407.81	1,120,365,125.73
	1,662,373,054.64	1,662,373,054.64
G		
	6,700,890,376.05	5,457,045,050.64
F		
	17,562,820,440.09	16,674,848,786.15
N	2,368,298,318.73	2,428,153,101.51
	19,931,118,758.82	19,103,001,887.66
	37,414,560,945.71	35,336,277,255.96

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia



Balance Sheet of the Parent Company (Continued)
30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
	1,834,226,000.00	
F		
B		
	78,632,661.11	72,568,579.44
	23,932,653.33	21,842,286.49
I	147,159,729.00	160,716,398.26
D	1,364,923.50	1,062,450.00
①	453,068,674.16	587,606,051.26
N	2,641,935,028.99	1,037,216,423.85
②		998,894,520.55
	5,180,319,670.09	2,879,906,709.85
Non-current liabilities:		
L	186,740,000.00	85,000,000.00
B	1,894,480,886.28	3,085,482,735.30
L		
A		
D	1,525,000.00	1,750,000.00
D	1,209,260,573.79	1,192,857,263.79
①		
	3,292,006,460.07	4,365,089,999.09
	8,472,326,130.16	7,244,996,708.94
Equity:		
	2,311,380,364.00	2,311,611,364.00
C	8,227,835,906.44	8,270,816,715.22
L		
①	55,747,958.04	224,689,817.57
	949,985,460.52	949,985,460.52
G		
	4,193,926,575.18	2,839,595,396.66
	15,738,876,264.18	14,596,698,753.97
	24,211,202,394.34	21,841,695,462.91

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Consolidated Income Statement (Continued)

January – September 2015

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
	-503,674,636.21	170,383,244.67	-279,141,519.38	146,057,212.28
	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
()				
1. C				
2.				
()	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
1.	732,427.55	-9,352.18	-195,739,333.69	-5,108,705.95
2. C	-440,970,255.91	171,599,596.74	-16,216,735.14	149,088,050.35
3. G				
4. E				
5. E	-65,806,450.80	-1,851,673.11	-69,940,649.09	3,828,899.96
6.				
	2,369,642.95	644,673.22	2,755,198.54	-1,751,032.08
	157,117,103.71	812,100,177.38	1,897,755,696.77	1,940,074,283.26
	81,440,708.74	726,766,676.07	1,609,072,739.39	1,722,392,108.74
	75,676,394.97	85,333,501.31	288,682,957.38	217,682,174.52
III. E				
(1)	0.25	0.24	0.82	0.69
(2)	0.25	0.24	0.82	0.69

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Consolidated Statement of Cash Flow (Continued)

January – September 2015

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
III. Cash flow generated from financing activities:		
Cash received from the sale of equity securities	87,721,195.00	1,445,949,451.00
Interest received on cash equivalents	87,721,195.00	38,269,850.07
Cash received from the sale of property, plant and equipment	5,110,056,682.54	3,475,109,758.30
Cash received from the sale of investments	398,929,000.00	1,000,000,000.00
Proceeds from the issuance of debt	40,140,014.05	21,733,509.09
Proceeds from the sale of investments	5,636,846,891.59	5,942,792,718.39
Cash received from the sale of investments	3,519,139,442.58	1,623,242,732.68
Cash received from the sale of investments	1,114,614,719.91	1,012,768,967.52
Interest received on cash equivalents	268,686,768.21	133,554,721.22
Proceeds from the sale of investments	238,690,425.98	1,512,793,278.03
Proceeds from the sale of investments	4,872,444,588.47	4,148,804,978.23
Net change in cash and cash equivalents	764,402,303.12	1,793,987,740.16
IV. Effects of exchange rate fluctuations on cash and cash equivalents	5,949,548.99	14,780,312.38
V. Net increase of cash and cash equivalents	28,667,545.61	8

